BIO-RAD LABORATORIES, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
BIO-RAD LABORATORIES, INC. (BIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $19.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-04
- BIO-RAD LABORATORIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $9.50M, a 5.00% decline year-over-year.
- BIO-RAD LABORATORIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $9.70M, a 3.96% decline year-over-year.
- BIO-RAD LABORATORIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $10.00M, a 1.96% decline year-over-year.
- BIO-RAD LABORATORIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $10.00M, a 1.96% decline year-over-year.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $19.20M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $9.70M 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $20.00M derived: sum of 2 quarters · filed 2026-08-04 | $30.10M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $20.10M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $10.10M 10-Q · filed 2026-04-30 | ||
| 2024-09-30 | $10.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $20.40M derived: sum of 2 quarters · filed 2025-10-29 | $31.10M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $10.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $20.90M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $10.70M 10-Q · filed 2025-05-01 | ||
| 2023-09-30 | $10.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $20.70M derived: sum of 2 quarters · filed 2024-10-31 | $30.70M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $19.90M 10-Q · filed 2024-08-02 | |
| 2023-03-31 | $10.00M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $9.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | $19.80M derived: sum of 2 quarters · filed 2023-10-27 | $29.80M 10-Q · filed 2023-10-27 |
| 2022-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $20.00M 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $10.00M 10-Q · filed 2023-05-05 | ||
| 2021-09-30 | $9.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $19.50M derived: sum of 2 quarters · filed 2022-10-28 | $29.30M 10-Q · filed 2022-10-28 |
| 2021-06-30 | $9.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $19.60M 10-Q · filed 2022-07-29 | |
| 2021-03-31 | $9.80M 10-Q · filed 2022-04-29 | ||
| 2020-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $18.10M derived: sum of 2 quarters · filed 2021-10-29 | $27.70M 10-Q · filed 2021-10-29 |
| 2020-06-30 | $9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $18.70M 10-Q · filed 2021-07-30 | |
| 2020-03-31 | $9.60M 10-Q · filed 2021-04-30 | ||
| 2019-09-30 | $11.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $31.10M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $19.80M 10-Q · filed 2020-07-31 |